Evidence map›Paper›PMID 27738167›Full record

ArticleScience (New York, N.Y.)2016

Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy.

Siddappa N Byrareddy, James Arthos, Claudia Cicala, Francois Villinger, Kristina T Ortiz, Dawn Little, Neil Sidell, Maureen A Kane, Jianshi Yu, Jace W Jones and 19 more

Retracted Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. It is linked to trial NCT03577782 (Phase II Clinical Trial to Analyze the Safety and Efficacy of Vedolizumab Combined With Antiretroviral Therapy to Achieve Permanent Virological Remission in HIV-infected Subjects Without Previous Antiretroviral Therapy), which is not on this map. Cited by 134 papers.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed
23.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03577782 phase1 / phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Phase II Clinical Trial to Analyze the Safety and Efficacy of Vedolizumab Combined With Antiretroviral Therapy to Achieve Permanent Virological Remission in HIV-infected Subjects Without Previous Antiretroviral Therapy

TypeinterventionalSponsorHospitales Universitarios Virgen del RocíoRan2018 to 2020Enrolled12ConditionsHIV InfectionsArmsEntyvio (Vedolizumab)
3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 201 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 6 institutions in 3 countries.

Siddappa N ByrareddyDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
James ArthosLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD 20892, USA.
Claudia CicalaLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD 20892, USA.
Francois VillingerDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA. Division of Pathology, The Yerkes National Primate Center of Emory University, Atlanta, GA 30329, USA.
Kristina T OrtizDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Dawn LittleDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Neil SidellDepartment of Obstetrics and Gynecology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Maureen A KaneDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA.
Jianshi YuDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA.
Jace W JonesDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA.
Philip J SantangeloWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30680, USA.
Chiara ZurlaWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30680, USA.
Lyle R McKinnonCentre for the AIDS Program of Research in South Africa (CAPRISA), Durban, South Africa.
Kelly B ArnoldDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Caroline E WoodyDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Lutz WalterPrimate Genetics Laboratory, German Primate Center, Leibniz Institute for Primate Research, Göttingen, Germany.
Christian RoosPrimate Genetics Laboratory, German Primate Center, Leibniz Institute for Primate Research, Göttingen, Germany.
Angela NollPrimate Genetics Laboratory, German Primate Center, Leibniz Institute for Primate Research, Göttingen, Germany.
Donald Van RykLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD 20892, USA.
Katija JelicicLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD 20892, USA.
Raffaello CimbroDivision of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD 21201, USA.
Sanjeev GumberDivision of Pathology, The Yerkes National Primate Center of Emory University, Atlanta, GA 30329, USA.
Michelle D ReidDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Volkan AdsayDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Praveen K AmanchaDivision of Pathology, The Yerkes National Primate Center of Emory University, Atlanta, GA 30329, USA.
Ann E MayneDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Tristram G ParslowDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Anthony S FauciLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD 20892, USA.
Aftab A AnsariDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA. pathaaa@emory.edu.
Emory University · USNational Institute of Allergy and Infectious Diseases · USGerman Primate Center · DEUniversity of Maryland, Baltimore · USUniversity of Michigan–Ann Arbor · USCentre for the AIDS Programme of Research in South Africa · ZA

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI RENGARAJAN, JYOTHI · 1985 to 2011
$114.0M
Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1M
Role of HIV Envelope Proteins In Viral Replication and HIV PathogenesisZIAAI000887 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CICALA, CLAUDIA · 2009 to 2025
$15.2M
Interaction of HIV envelope with cell surface receptorsZIAAI000883 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ARTHOS, JAMES L · 2009 to 2024
$14.0M
Gut Homing Cells in SIV infectionR01AI098628 · NIAID · EMORY UNIVERSITY · PI ANSARI, AFTAB A. · 2012 to 2016
$7.0M
Monitoring SIV Reservoirs with Whole Body immunoPETR01AI111907 · NIAID · UNIVERSITY OF LOUISIANA AT LAFAYETTE · PI SANTANGELO, PHILIP J, VILLINGER, FRANCOIS J · 2014 to 2018
$5.8M
Resource for Nonhuman Primate Immune ReagentsR24OD010947 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VILLINGER, FRANCOIS J · 2012 to 2025
$4.9M
Resource for Nonhuman Primate Cell Depleting AntibodiesR24OD010976 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ENGELMAN, KATHLEEN, MAGNANI, DIOGO · 2012 to 2019
$4.7M
Nebraska Center for VirologyP30GM103509 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI WOOD, CHARLES · 2012 to 2014
$3.3M
Evaluation of Iron Species in Healthy Subjects Treated with Generic and Reference Sodium Ferric GluconateU01FD005266 · FDA · UNIVERSITY OF MARYLAND BALTIMORE · PI KANE, MAUREEN A, MICHEL, SARAH L · 2014 to 2018
$2.0M
Molecular determinants of retinoid metabolism in embryonic tissuesR01HD077260 · NICHD · UNIVERSITY OF MARYLAND BALTIMORE · PI KANE, MAUREEN A, MOISE, ALEX RADU · 2014 to 2018
$1.6M
FDA HHS U01 FD005266NCRR NIH HHS P51 RR000165NIAID NIH HHS R01 AI098628NIAID NIH HHS R01 AI111907NIAID NIH HHS U24 AI126683NICHD NIH HHS R01 HD077260NIGMS NIH HHS P30 GM103509NIH HHS P51 OD011132NIH HHS R24 OD010947NIH HHS R24 OD010976
6 · The paper itself

Abstract

Antiretroviral drug therapy (ART) effectively suppresses replication of both the immunodeficiency viruses, human (HIV) and simian (SIV); however, virus rebounds soon after ART is withdrawn. SIV-infected monkeys were treated with a 90-day course of ART initiated at 5 weeks post infection followed at 9 weeks post infection by infusions of a primatized monoclonal antibody against the α

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCD4 Lymphocyte CountCD4-Positive T-LymphocytesCombined Modality TherapyCytokinesDisease Models, AnimalFemaleGastrointestinal TractImmunization, PassiveInfusions, IntravenousIntegrin alpha4Integrin beta ChainsKiller Cells, NaturalMacaca mulattaAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCytokinesgp120 protein, Simian immunodeficiency virusIntegrin alpha4integrin beta7Integrin beta ChainsMembrane GlycoproteinsTretinoinvedolizumabViral Envelope Proteins

Identifiers

PMID27738167
PMCPMC5405455
OpenAlexW2531054429

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.